BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:26 PM
 | 
Aug 28, 2012
 |  BC Extra  |  Company News

EC approves Novartis' Jakavi for myelofibrosis

The European Commission approved Jakavi ruxolitinib from Novartis AG (NYSE:NVS; SIX:NOVN) to treat chronic idiopathic myelofibrosis, post-polycythemia vera or essential thrombocythemia...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >